SpliceBio
About
What does SpliceBio do?
SpliceBio is a biotechnology company focused on developing next-generation gene therapies. Their proprietary Protein Splicing platform is designed to overcome the limitations of traditional gene therapy by enabling the delivery of large genes, which are often implicated in genetic diseases. This technology is based on extensive research in protein engineering and intein biology, originating from Princeton University, and aims to provide new therapeutic options for diseases currently lacking effe…
What is SpliceBio's revenue?
StartupHub estimates SpliceBio's annual revenue at $14.4M (range $4.9M to $42.0M, 34% confidence), based on comparable companies in the sector.
What is SpliceBio's valuation?
StartupHub estimates SpliceBio's effective valuation at $399.8M (range $250.0M to $600.0M, 12% confidence), based on comparable companies in the sector.
How much funding has SpliceBio raised?
SpliceBio has raised a total of $100M in funding. The most recent round on record is Series B.
Where is SpliceBio headquartered?
SpliceBio is headquartered in Cambridge, United States.
When was SpliceBio founded?
SpliceBio was founded in 2021.
What industry does SpliceBio operate in?
SpliceBio operates in Biotechnology, HealthTech, Gene Therapy, Biotech, Drug Discovery, Genomics.
What is SpliceBio's current status?
SpliceBio's current operating status is: Inactive.
No comments yet. Be the first to share your take.